Calderón E, Conde C J, de la Cruz R, Narcio L, Hirata C
Departmento de Infectología e Immunología Perinatal, Instituto Nacional de Perinatología, México, D.F.
Diagn Microbiol Infect Dis. 1987 Sep;8(1):13-8. doi: 10.1016/0732-8893(87)90041-1.
Since being recognized in 1976 and 1983, respectively, penicillinase-producing strains of Neisseria gonorrhoeae (PPNG) and chromosomally mediated resistance (CMRNG) have attained a worldwide distribution. The high endemicity of both types of resistance in some regions precludes the continued routine use of procaine penicillin (APPG) as treatment for gonorrhea. In this study, we have evaluated 72/216 men with uncomplicated gonococcal urethritis at the venereal clinic in Mexico City. These men were part of a blinded randomized comparative study for treatment with group (P) penicillin having 33 patients and group (S) spectinomycin having 39. Efficacy with (P) was 24/33 (72.7%); nine failures retreated and were cured with spectinomycin. Efficacy with (S) was 35/39 (89.7%); four failures retreated and were cured with cefotaxime. We found correlation between MICs and resistance; all the strains with MICs of greater than or equal to 1.0 mcg/ml of penicillin failed to be cured, the MICs of greater than or equal to 32 mcg/ml of spectinomycin failed to be cured. The overall resistance to both regimens was 23/72 to penicillin (31.9%) (22 PPNG and one CMRNG) and 4/72 (5.5%) to spectinomycin.
自1976年和1983年分别被发现以来,产青霉素酶的淋病奈瑟菌(PPNG)菌株和染色体介导的耐药性(CMRNG)已在全球范围内传播。在某些地区,这两种耐药类型的高流行率使得普鲁卡因青霉素(APPG)无法继续作为淋病治疗的常规用药。在本研究中,我们对墨西哥城性病诊所72/216例患有单纯性淋菌性尿道炎的男性进行了评估。这些男性是一项双盲随机对照研究的一部分,该研究中,33例患者接受(P)组青霉素治疗,39例患者接受(S)组壮观霉素治疗。(P)组的有效率为24/33(72.7%);9例治疗失败后改用壮观霉素治疗并治愈。(S)组的有效率为35/39(89.7%);4例治疗失败后改用头孢噻肟治疗并治愈。我们发现最低抑菌浓度(MIC)与耐药性之间存在相关性;所有青霉素MIC大于或等于1.0 mcg/ml的菌株治疗均未成功,壮观霉素MIC大于或等于32 mcg/ml的菌株治疗也未成功。两种治疗方案的总体耐药率分别为:青霉素23/72(31.9%)(22株PPNG和1株CMRNG),壮观霉素4/72(5.5%)。